Clinical Trials in Utrecht, Netherlands
6 recruiting
Showing 1–18 of 18 trials
Recruiting
Phase 3
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC600 enrolled212 locationsNCT06345729
Recruiting
Phase 1
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Non-small Cell Lung CancerPancreatic Ductal AdenocarcinomaHR+/HER2- Ductal and Lobular Breast Cancer
Novartis Pharmaceuticals162 enrolled30 locationsNCT06562192
Recruiting
Phase 3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Eli Lilly and Company1,264 enrolled424 locationsNCT06119581
Recruiting
Spectral Cancer Tissue Recognition - I
Breast CancerMargin Assessment
SPCTR100 enrolled2 locationsNCT07459062
Recruiting
The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
Breast CancerLiver CancerEsophageal Cancer+35 more
UMC Utrecht8,000 enrolled18 locationsNCT04075305
Recruiting
Phase 1
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Breast NeoplasmsCholangiocarcinomaOvarian Neoplasms+4 more
Eli Lilly and Company241 enrolled27 locationsNCT07213791
Recruiting
Phase 1
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
KRAS Altered Advanced or Metastatic Solid Tumors
Amgen434 enrolled27 locationsNCT07094113
Recruiting
Phase 2
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
Recurrent or Metastatic Solid Tumors
Daiichi Sankyo520 enrolled119 locationsNCT06330064
Recruiting
Not Applicable
Finding Sentinel Lymph Nodes During Mastectomy Using Indocyanine Green (INIGMA Study)
Breast CancerMastectomySentinel Lymph Node Biopsy (SLNB)+7 more
Isabelle Henskens90 enrolled2 locationsNCT07362485
Recruiting
Not Applicable
Implementation of Indocyanine Green to Identify Sentinel Lymph Nodes During Surgery for Breast Cancer
Breast CancerSentinel Lymph Node Biopsy (SLNB)Sentinel Lymph Node Detection+6 more
Isabelle Henskens1,760 enrolled7 locationsNCT07146295
Recruiting
Phase 3
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Breast Cancer
Pfizer400 enrolled153 locationsNCT07062965
Recruiting
Phase 3
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
European Organisation for Research and Treatment of Cancer - EORTC220 enrolled94 locationsNCT05512364
Recruiting
Phase 1Phase 2
Study of DF1001 in Patients with Advanced Solid Tumors
Solid Tumor, Adult
Dragonfly Therapeutics378 enrolled52 locationsNCT04143711
Recruiting
Phase 2
COntinue the SaMe Systemic Therapy After Local Ablative Therapy for Oligo Progression in Metastatic Breast Cancer - the COSMO Study
Breast Cancer InvasiveMetastatic CancerOligoprogressive
The Netherlands Cancer Institute118 enrolled7 locationsNCT05301881
Recruiting
Not Applicable
Supplemental Screening for Women With Extremely Dense Breast Tissue: the DENSE-2 Trial
Breast Cancer
C.H. van Gils36,000 enrolled1 locationNCT06636370
Recruiting
Not Applicable
Cancer Of the BReast Asanas Study (COBRA)
Breast Cancer
UMC Utrecht140 enrolled1 locationNCT06480513
Recruiting
Utrecht Cohort for Multiple Breast Cancer Intervention Studies and Long-term Evaluation - The UMBRELLA Cohort
Breast Cancer
UMC Utrecht10,000 enrolled4 locationsNCT02839863
Recruiting
Minimal Invasive Axillary Staging and Treatment After Neoadjuvant Systemic Therapy in Node Positive Breast Cancer
Breast CancerNeoadjuvant TherapyLymph Node Metastases
Maastricht University Medical Center549 enrolled35 locationsNCT04486495